Alloy Safety, Regulation & Compliance: An Independent Review

What Is Alloy and Is It a Legitimate Medical Service?

Alloy is a legitimate telehealth company. It operates under the same basic legal framework that governs other U.S. Telehealth prescribers: clinicians hold active state licenses, prescriptions are issued through electronic health records, and pharmacies filling orders must meet either FDA-approval standards or federal 503A/503B compounding rules.

"legitimate" is not the same as "right for every patient." Alloy's model depends heavily on asynchronous intake forms rather than live video visits for initial consultations. That process works well for straightforward cases, but it may miss nuanced history-taking that a face-to-face endocrinologist or OB-GYN visit would catch. Patients with complex medical histories, prior breast cancer, or cardiovascular disease should weigh whether async telehealth is sufficient for their needs.

Who Owns and Operates Alloy?

Alloy was co-founded in 2019 by Monica Molenaar and Anne Fulenwider. The company is venture-backed and has publicly described its mission as expanding access to evidence-based menopause care. Unlike some direct-to-consumer hormone platforms that rely on a single contracted medical group, Alloy states it works with a network of licensed clinicians across multiple states.

Prescribing Clinicians and Licensure

Alloy's clinical team includes physicians and advanced practice providers. Each clinician prescribing through the platform must hold a valid license in the patient's state of residence. This is a non-negotiable legal requirement under the federal Ryan Haight Act and individual state telehealth statutes. No evidence has emerged in public regulatory records indicating that Alloy or its prescribers have faced disciplinary action from state medical boards, though patients can independently verify prescriber licenses through their state's medical board directory.

The Hormones Alloy Prescribes: What the Evidence Says

Alloy prescribes several forms of estrogen and progesterone to address common menopause symptoms including vasomotor symptoms, genitourinary syndrome, and sleep disruption. The product mix includes FDA-approved estradiol patches (such as generic versions of Climara or Vivelle-Dot), oral micronized progesterone (Prometrium or generic), vaginal estradiol cream, and compounded hormone preparations.

FDA-Approved Products

FDA-approved estradiol and progesterone formulations carry the strongest safety evidence. The Women's Health Initiative (WHI), which enrolled 27,347 women, produced data that initially alarmed clinicians, but subsequent reanalysis clarified that the timing of initiation matters substantially. Women who began hormone therapy within 10 years of menopause onset or before age 60 showed a more favorable benefit-to-risk profile than older women with longer gaps since menopause. The North American Menopause Society (NAMS) summarized this as the "timing hypothesis" in its 2022 Hormone Therapy Position Statement. [1]

Transdermal estradiol in particular carries a lower venous thromboembolism (VTE) risk than oral estrogen. A 2019 BMJ case-control study (N=80,396) found that transdermal estradiol was not associated with increased VTE risk, while oral estrogens were associated with an odds ratio of approximately 1.58. [2] Alloy's emphasis on transdermal delivery aligns with this evidence.

Compounded Hormones: The Regulatory Gray Zone

Alloy also offers compounded hormone preparations. This is where the regulatory picture becomes more complicated, and patients deserve a clear-eyed explanation.

Compounded hormones are mixed by pharmacies under either 503A (patient-specific, traditional compounding) or 503B (outsourcing facility) rules. They are not FDA-approved. The FDA has not evaluated compounded preparations for safety, efficacy, or consistent potency. Batch-to-batch variability is a documented concern. [3]

NAMS, ACOG, and the Endocrine Society have consistently stated that compounded "bioidentical" hormones should not be preferred over FDA-approved alternatives. The NAMS 2022 Position Statement states explicitly: "Compounded bioidentical hormones are not recommended as a preferred form of hormone therapy due to the lack of regulatory oversight and absence of clinical trial data supporting their safety and efficacy." [1]

Compounded bi-estrogen (bi-est) or tri-estrogen (tri-est) formulations, which some telehealth platforms offer, have no peer-reviewed efficacy data and no FDA-approved equivalents. If Alloy's clinicians prescribe these, patients should ask specifically why a non-approved formulation is being chosen over an FDA-approved alternative.

Progesterone vs. Synthetic Progestins

One area where Alloy's approach is clinically sound: the use of micronized progesterone (Prometrium) rather than medroxyprogesterone acetate (MPA). The WHI used MPA, which contributed to an increased breast cancer signal in the combined therapy arm. Observational data from the French E3N cohort (N=80,377, follow-up over 8 years) showed that combined estradiol plus micronized progesterone was not associated with increased breast cancer risk in the first 5 years of use, unlike estrogen plus synthetic progestins. [4] Prescribing micronized progesterone is consistent with current best practice.

Regulatory and Compliance Framework

Federal Oversight of Telehealth Prescribing

Alloy operates as a prescribing platform, not a manufacturer. Federal oversight of the prescribing side comes primarily from the Drug Enforcement Administration (DEA) for controlled substances, the Ryan Haight Online Pharmacy Consumer Protection Act for controlled substance prescribing, and individual state medical practice laws.

Hormone therapy drugs (estradiol, progesterone) are not DEA-controlled substances, so the strictest telemedicine prescribing restrictions under the Ryan Haight Act do not apply. This gives Alloy and similar platforms wide legal latitude to prescribe via asynchronous encounters. That latitude is a policy choice, not a safety guarantee.

Pharmacy Partners and USP Standards

Compounding pharmacies filling Alloy prescriptions should comply with USP Chapter 795 (non-sterile preparations) and, for sterile products, USP Chapter 797. Patients can ask Alloy directly which pharmacies fulfill their prescriptions and whether those pharmacies are PCAB-accredited (Pharmacy Compounding Accreditation Board). PCAB accreditation is voluntary but signals higher quality standards.

The FDA's MedWatch system has received adverse event reports related to compounded hormone products from various sources. These reports are publicly searchable at accessdata.fda.gov. No specific data is publicly available linking adverse events to Alloy's specific pharmacy partners, but the general risk class applies.

State-by-State Availability

Alloy is not available in all 50 states. Some states impose additional requirements on telehealth prescribing or restrict certain compounded products. Patients should confirm availability in their state at the time of enrollment, as the list changes.

How Alloy Compares to Alternatives

The table below provides a comparative framework for evaluating Alloy against the main categories of menopause care access. This framework was developed by the HealthRX clinical team and is not reproduced from any single competitor source.

| Feature | Alloy | Traditional OB-GYN or PCP | Midi Health | Evernow | In-person menopause specialist | |---|---|---|---|---|---| | Consult type | Async + optional sync | In-person | Sync video | Async | In-person | | FDA-approved products | Yes | Yes | Yes | Yes | Yes | | Compounded hormones offered | Yes | Rarely | Limited | Limited | Varies | | Insurance accepted | No (cash pay) | Yes | Yes | No | Yes | | Average monthly cost | $49-$99 | Varies with copay | $35-$65/visit | $25-$75 | $150+ out of pocket | | NAMS-aligned protocols | Broadly yes | Varies by provider | Broadly yes | Broadly yes | Yes (specialists) | | Prescriber credentials visible | Partial | Yes | Yes | Partial | Yes |

Key takeaway: Alloy's cash-pay model makes it accessible without insurance authorization delays. The tradeoff is no insurance coverage and the asynchronous consultation format, which some patients find impersonal or insufficient for complex cases.

Alloy vs. Midi Health

Midi Health uses synchronous video visits with menopause-trained clinicians and accepts major insurance plans. For patients who want a live conversation before starting hormones, Midi may be more appropriate. Alloy's async model moves faster and may suit women who have already done significant research and want to start a straightforward regimen.

Alloy vs. Seeing an In-Person Specialist

An in-person menopause specialist, particularly one certified by NAMS (a list of NAMS-certified menopause practitioners is searchable at menopause.org), offers the most thorough evaluation. For women with prior hormone-sensitive cancer, cardiovascular disease, or unclear diagnosis, an in-person specialist visit before starting any telehealth hormone program is the safest path.

Safety Profile of Menopausal Hormone Therapy: The Evidence Baseline

Any assessment of Alloy's safety must be contextualized against the broader evidence base for hormone therapy (HT) itself.

Cardiovascular Risk

The WHI CEE-plus-MPA arm (N=16,608) showed a small absolute increase in coronary heart disease events, but the relative risk was concentrated in women who were more than 10 years post-menopause or older than 70 at initiation. [5] For women aged 50 to 59 initiating transdermal estradiol (the form Alloy commonly prescribes), the cardiovascular picture is considerably more favorable. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) found no significant difference in progression of subclinical atherosclerosis between estradiol and placebo over 4 years in recently menopausal women. [6]

Breast Cancer Risk

Breast cancer risk with HT remains the most discussed concern. The Million Women Study (N=1,084,110) showed that combined estrogen-progestogen therapy was associated with a higher breast cancer risk than estrogen alone. [7] Using transdermal estradiol plus micronized progesterone, as Alloy does in many of its regimens, carries a more favorable signal than the combined oral formulations studied in WHI. The absolute risk increase for a woman taking combined HT for 5 years is approximately 5 extra cases per 1,000 women, per the NAMS 2022 summary. [1]

VTE Risk

As noted above, transdermal estradiol does not appear to carry the VTE risk associated with oral estrogen. [2] Women with prior VTE, Factor V Leiden, or other thrombophilias should discuss their history thoroughly before starting any hormone therapy.

Who Should Not Use Alloy (Or Any HRT Platform Without Specialist Input)

• Personal or family history of BRCA1/BRCA2-positive breast cancer
• Active or recent (within 12 months) VTE or pulmonary embolism
• Undiagnosed abnormal uterine bleeding
• Active liver disease
• Known or suspected hormone-sensitive cancer

These are absolute or relative contraindications under the NAMS 2022 guidelines. [1] An asynchronous intake form may not capture all of these with the same rigor as a structured in-person history.

What Real Patients Say: Reviews in Clinical Context

Alloy holds generally positive consumer reviews on platforms like Trustpilot, with many patients reporting rapid relief from vasomotor symptoms and straightforward prescription delivery. Common positive themes include ease of access, fast shipping, and responsive customer support. Common complaints include difficulty reaching clinicians for follow-up questions, limited formulary options in some states, and the cost of ongoing prescriptions without insurance coverage.

Patient reviews should not be treated as clinical evidence, but they do signal operational patterns. A recurring theme across multiple third-party review sites is that some patients felt uncertain about dose adjustments without synchronous clinician access. This is a structural limitation of the async-first model, and it is worth factoring into a decision.

Compliance With Menopause Clinical Guidelines

NAMS 2022 Position Statement Alignment

The NAMS 2022 Hormone Therapy Position Statement is the most authoritative U.S. Guideline for menopause management. It endorses hormone therapy for bothersome vasomotor symptoms in healthy, recently menopausal women under 60. It recommends the lowest effective dose for the shortest duration consistent with treatment goals while periodically reassessing the need for continuation. [1]

Alloy's stated protocols align with this framework: transdermal estradiol, micronized progesterone for women with a uterus, and dosing adjustments based on symptom response. The alignment is genuine but incomplete. Alloy does not appear to offer the same level of baseline cardiovascular or bone density screening that a structured menopause clinic would provide before prescribing.

ACOG Committee Opinion on Compounded Hormones

ACOG Committee Opinion 532 (reaffirmed 2022) states that "compounded hormones lack the rigorous clinical testing of FDA-approved products, and patients should be counseled that these preparations may carry unknown risks." [8] Patients receiving compounded hormones from Alloy should receive this counseling proactively, and they should ask whether an FDA-approved alternative is available before accepting a compounded preparation.

Cost Breakdown: What Alloy Actually Charges

Alloy operates on a direct-pay model with no insurance billing. As of mid-2025, pricing structures reported by users and Alloy's own published pages suggest:

• Initial consultation fee: approximately $20 to $49 (varies by promotion)
• Monthly prescription costs: approximately $49 to $99 depending on formulation
• Patch-based regimens tend to cost slightly more than oral formulations
• Compounded preparations may be priced differently than FDA-approved products

These costs are not reimbursable through most commercial insurance or Medicare. Patients with HSA or FSA accounts may be able to use pre-tax dollars for these expenses, but should confirm with their plan administrator. The out-of-pocket cost is competitive relative to traditional care with copays plus pharmacy costs, particularly for patients whose insurance does not cover hormone therapy.

Clinical Red Flags to Watch For

Not every concern about a telehealth HRT platform is disqualifying, but these specific patterns should prompt a patient to ask harder questions or seek a second opinion:

1. A clinician prescribes compounded bi-est or tri-est without explaining why an FDA-approved estradiol product would not work.
2. No baseline assessment of cardiovascular risk factors before initiating therapy.
3. No recommendation for a follow-up visit or lab check within the first 3 to 6 months.
4. Progesterone is omitted for a patient who still has a uterus (this would be medically inappropriate; unopposed estrogen raises endometrial cancer risk).
5. The platform discourages patients from sharing their HRT regimen with their primary care physician.

None of these red flags appear to be systematic Alloy policy based on publicly available information, but individual prescribers vary. Patients should maintain open communication with their primary care team regardless of which platform they use.